Figure 2. Use of Laboratory Testing to Select Initial Treatment for Accelerated- or Blast-Phase CML

This algorithm is intended as a guide for using Quest Diagnostics tests to predict tyrosine kinase inhibitor response in patients with accelerated- or blast-phase CML. The algorithm is based on the National Comprehensive Cancer Network and the European LeukemiaNet guidelines. It is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

Note that first-line therapy for chronic-phase CML is imatinib, dasatinib, or nilotinib. CML indicates chronic myelogenous leukemia; TKI, tyrosine kinase inhibitor.

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third party marks - ® and ™ - are the property of their respective owners. © 2012 Quest Diagnostics Incorporated. All rights reserved.

Content reviewed 12/2012